drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti-SLAMF7)
drug_description
Humanized monoclonal antibody targeting SLAMF7/CS1, used to arm T cells by binding SLAMF7 on myeloma cells to facilitate immune synapse formation.
nci_thesaurus_concept_id
C66982
nci_thesaurus_preferred_term
Elotuzumab
nci_thesaurus_definition
A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.
drug_mesh_term
Elotuzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting SLAMF7/CS1. By binding SLAMF7 on multiple myeloma cells and engaging Fcγ receptors on NK cells, it triggers antibody-dependent cellular cytotoxicity (ADCC) and can co-activate NK cells via SLAMF7 signaling, leading to immune-mediated killing of SLAMF7+ myeloma cells.
drug_name
Elotuzumab
nct_id_drug_ref
NCT04864522